Evaluation of the intravenous and topical routes for ocular delivery of hesperidin and hesperetin

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 6, 2012, Pages 618-627

  Srirangam, Ramesh ^a   Hippalgaonkar, Ketan ^a   Avula, Bharathi ^b,c   Khan, Ikhlas A ^a,b,c   Majumdar, Soumyajit ^a,b,c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; BETA GLUCURONIDASE; BIOFLAVONOID; GLUCURONIDE; HESPERETIN; HESPERIDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; EXPERIMENTAL RABBIT; HYDROPHILICITY; MALE; NONHUMAN; POSTERIOR EYE SEGMENT; SYSTEMIC CIRCULATION; VITREOUS BODY;

ADMINISTRATION, OPHTHALMIC; ANIMALS; BENZALKONIUM COMPOUNDS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FEASIBILITY STUDIES; GLUCURONIDES; HESPERIDIN; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INJECTIONS, INTRAVENOUS; MALE; RABBITS; TIME FACTORS; VITREOUS BODY;

EID: 84869450839     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0040     Document Type: Article

References (54)

1. Ciulla, T.A., Amador, A.G., and Zinman, B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 26:2653-2664, 2003. (Pubitemid 37055447)
2. Chiou, G.C., and Xu, X.R. Effects of some natural flavonoids on retinal function recovery after ischemic insult in the rat. J. Ocul. Pharmacol. Ther. 20:107-113, 2004. (Pubitemid 38456583)
3. Calderone, V., Chericoni, S., Martinelli, C., et al. Vasorelaxing effects of flavonoids: investigation on the possible involvement of potassium channels. Naunyn Schmiedebergs Arch. Pharmacol. 370:290-298, 2004. (Pubitemid 40063828)
4. Manthey, J.A. Biological properties of flavonoids pertaining to inflammation. Microcirculation. 7:S29-S34, 2000.
5. Bouskela, E, Cyrino, F.Z., and Marcelon, G. Inhibitory effect of the Ruscus extract and of the flavonoid hesperidine methylchalcone on increased microvascular permeability induced by various agents in the hamster cheek pouch. J. Cardiovasc. Pharmacol. 22:225-230, 1993. (Pubitemid 23225148)
6. Korthuis, R.J., and Gute, D.C. Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. J. Vasc. Res. 36 Suppl 1:15-23, 1999. (Pubitemid 29411271)
7. McGregor, L., Bellangeon, M., Chignier, E., Lerond, L., Rousselle, C., and McGregor, J.L. Effect of a micronized purified flavonoid fraction on in vivo platelet functions in the rat. Thromb. Res. 94:235-240, 1999. (Pubitemid 29238351)
8. Xiaoting, L., Xiangyun, Z., Shumei, L., Minghua, D., and Liang, X. Effect of hesperidin on expression of inducible nitric oxide synthase in cultured rabbit retinal pigment epithelial cells. Adv. Exp. Med. Biol. 664:193-201, 2010.
9. Choi, E.J., Kim, G.D., Chee, K.M., and Kim, G.H. Effects of hesperetin on vessel structure formation in mouse embryonic stem (mES) cells. Nutrition. 22:947-951, 2006. (Pubitemid 44234009)
10. Choi, I.Y., Kim, S.J., Jeong, H.J., et al. Hesperidin inhibits expression of hypoxia inducible factor-1 alpha and inflammatory cytokine production from mast cells. Mol. Cell. Biochem. 305:153-161, 2007.
11. Hirata, A., Murakami, Y., Shoji, M., Kadoma, Y., and Fujisawa, S. Kinetics of radical-scavenging activity of hesperetin and hesperidin and their inhibitory activity on COX-2 expression. Anticancer Res. 25:3367-3374, 2005. (Pubitemid 41105213)
12. Majumdar, S., and Srirangam, R. Potential of the bioflavonoids in the prevention/treatment of ocular disorders. J. Pharm. Pharmacol. 62:951-965, 2010.
13. Ameer, B., Weintraub, R.A., Johnson, J.V., Yost, R.A., and Rouseff, R.L. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin. Pharmacol. Ther. 60:34- 40, 1996. (Pubitemid 26279218)
14. Manach, C., Morand, C., Gil-Izquierdo, A., Bouteloup- Demange, C., and Remesy, C. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur. J. Clin. Nutr. 57:235-242, 2003. (Pubitemid 36240474)
15. Garg, A., Garg, S., Zaneveld, L.J., and Singla, A.K. Chemistry and pharmacology of the Citrus bioflavonoid hesperidin. Phytother. Res. 15:655-669, 2001. (Pubitemid 34016792)
16. Brand, W., Boersma, M.G., Bik, H., et al. Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples. Drug Metab. Dispos. 38:617-625, 2010.
17. Breinholt, V.M., Offord, E.A., Brouwer, C., Nielsen, S.E., Brosen, K., and Friedberg, T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem. Toxicol. 40:609-616, 2002. (Pubitemid 34310426)
18. Gil-Izquierdo, A., Gil, M.I., Tomas-Barberan, F.A., and Ferreres, F. Influence of industrial processing on orange juice flavanone solubility and transformation to chalcones under gastrointestinal conditions. J. Agric. Food. Chem. 51:3024- 3028, 2003.
19. Ghate, D., and Edelhauser, H.F. Ocular drug delivery. Expert Opin. Drug Deliv. 3:275-287, 2006. (Pubitemid 43338097)
20. Maurice, D.M. Drug delivery to the posterior segment from drops. Surv. Ophthalmol. 47 Suppl 1:S41-S52, 2002. (Pubitemid 35232218)
21. Duvvuri, S., Majumdar, S., and Mitra, A.K. Drug delivery to the retina: challenges and opportunities. Expert Opin. Biol. Ther. 3:45-56, 2003. (Pubitemid 36193650)
22. Majumdar, S., Hippalgaonkar, K., and Srirangam, R. Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. Drug Metab. Dispos. 37:1718-1725, 2009.
23. Srirangam, R., Hippalgaonkar, K., and Majumdar, S. Intravitreal kinetics of hesperidin, hesperetin, and hesperidin G: effect of dose and physicochemical properties. J. Pharm. Sci. 101:1631-1638, 2012.
24. Majumdar, S., and Srirangam, R. Solubility, stability, physicochemical characteristics and in vitro ocular tissue permeability of hesperidin: a natural bioflavonoid. Pharm. Res. 26:1217-1225, 2009.
25. Srirangam, R., and Majumdar, S. Passive asymmetric transport of hesperetin across isolated rabbit cornea. Int. J. Pharm. 394:60-67, 2010.
26. Loftssona, T., and Jarvinen, T. Cyclodextrins in ophthalmic drug delivery. Adv. Drug Deliv. Rev. 36:59-79, 1999. (Pubitemid 29074477)
27. Kanaze, F.I., Bounartzi, M.I., Georgarakis, M., and Niopas, I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur. J. Clin. Nutr. 61:472-477, 2007. (Pubitemid 46605217)
28. Erlund, I., Meririnne, E., Alfthan, G., and Aro, A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J. Nutr. 131:235-241, 2001. (Pubitemid 32115362)
29. Matsumoto, H., Ikoma, Y., Sugiura, M., Yano, M., and Hasegawa, Y. Identification and quantification of the conjugated metabolites derived from orally administered hesperidin in rat plasma. J. Agric. Food Chem. 52:6653-6659, 2004.
30. Gardana, C., Guarnieri, S., Riso, P., Simonetti, P., and Porrini, M. Flavanone plasma pharmacokinetics from blood orange juice in human subjects. Br. J. Nutr. 98:165-172, 2007. (Pubitemid 47272161)
31. Choi, E.M., and Lee, Y.S. Effects of hesperetin on the production of inflammatory mediators in IL-1beta treated human synovial cells. Cell Immunol. 264:1-3, 2010.
32. Kuntz, S., Wenzel, U., and Daniel, H. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur. J. Nutr. 38:133-142, 1999. (Pubitemid 29352529)
33. Kalpana, K.B., Devipriya, N., Srinivasan, M., and Menon, V.P. Investigation of the radioprotective efficacy of hesperidin against gamma-radiation induced cellular damage in cultured human peripheral blood lymphocytes. Mutat. Res. 676:54-61, 2009.
34. Kalpana, K.B., Srinivasan, M., and Menon, V.P. Evaluation of antioxidant activity of hesperidin and its protective effect on H2O2 induced oxidative damage on pBR322 DNA and RBC cellular membrane. Mol. Cell Biochem. 323:21-29, 2009.
35. Chen, M.C., Ye, Y.Y., Ji, G., and Liu, J.W. Hesperidin upregulates heme oxygenase-1 to attenuate hydrogen peroxideinduced cell damage in hepatic L02 cells. J. Agric. Food Chem. 58:3330-3335, 2010.
36. Cos, P., Calomme, M., Sindambiwe, J.B., et al. Cytotoxicity and lipid peroxidation-inhibiting activity of flavonoids. Planta Med. 67:515-519, 2001. (Pubitemid 32800415)
37. Akiyama, S., Katsumata, S., Suzuki, K., Ishimi, Y., Wu, J., and Uehara, M. Dietary hesperidin exerts hypoglycemic and hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats. J. Clin. Biochem. Nutr. 46:87-92, 2010.
38. Stoclet, J.C., Chataigneau, T., Ndiaye, M., et al. Vascular protection by dietary polyphenols. Eur. J. Pharmacol. 500: 299-313, 2004. (Pubitemid 39304017)
39. Balakrishnan, A., and Menon, V.P. Antioxidant properties of hesperidin in nicotine-induced lung toxicity. Fundam. Clin. Pharmacol. 21:535-546, 2007. (Pubitemid 47404321)
40. Gandhi, C., Upaganalawar, A., and Balaraman, R. Protection against in vivo focal myocardial ischemia/reperfusion injury-induced arrhythmias and apoptosis by hesperidin. Free Radic. Res. 43:817-827, 2009.
41. Choi, E.J., and Ahn, W.S. Neuroprotective effects of chronic hesperetin administration in mice. Arch. Pharm. Res. 31:1457- 1462, 2008.
42. Kim, H., Csaky, K.G., Gravlin, L., et al. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina. 26:523- 530, 2006. (Pubitemid 44620393)
43. Burgalassi, S., Cappello, B., Chetoni, P., Iervolino, M., Monti, D., and Saettone, M.F. Rufloxacin eyedrops: effect of different formulations on ocular pharmacokinetics in rabbits. Eur. J. Ophthalmol. 16:311-317, 2006. (Pubitemid 43880056)
44. Gomes dos Santos, A.L., Bochot, A., Doyle, A., et al. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery. J. Controlled Release. 112:369-381, 2006. (Pubitemid 43737146)
45. Iyer, M.N., He, F., Wensel, T.G., Mieler, W.F., Benz, M.S., and Holz, E.R. Clearance of intravitreal moxifloxacin. Invest. Ophthalmol. Vis. Sci. 47:317-319, 2006. (Pubitemid 46780830)
46. Robinson, M.R., Lee, S.S., Kim, H., et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp. Eye Res. 82:479-487, 2006. (Pubitemid 43138962)
47. Kuppermann, B.D., and Loewenstein, A. Drug delivery to the posterior segment of the eye. Dev. Ophthalmol. 47:59-72, 2010.
48. Loftsson, T., Sigurdsson, H.H., Konradsdottir, F., Gisladottir, S., Jansook, P., and Stefansson, E. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie. 63:171-179, 2008. (Pubitemid 351449926)
49. Hippalgaonkar, K., Srirangam, R., Avula, B., Khan, I.A., and Majumdar, S. Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. Drug Metab. Dispos. 38:1790-1797, 2010.
50. Kaur, I.P., Chhabra, S., and Aggarwal, D. Role of cyclodextrins in ophthalmics. Curr. Drug Deliv. 1:351-360, 2004.
51. Okabe, K., Kimura, H., Okabe, J., et al. Effect of benzalkonium chloride on transscleral drug delivery. Invest. Ophthalmol. Vis. Sci. 46:703-708, 2005. (Pubitemid 40270355)
52. Majumdar, S., Hippalgaonkar, K., and Repka, M.A. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int. J. Pharm. 348:175-178, 2008. (Pubitemid 350266247)
53. Sasaki, H., Yamamura, K., Mukai, T., et al. Modification of ocular permeability of peptide drugs by absorption promoters. Biol. Pharm. Bull. 23:1524-1527, 2000. (Pubitemid 32016323)
54. Sasaki, H., Nagano, T., Yamamura, K., Nishida, K., and Nakamura, J. Ophthalmic preservatives as absorption promoters for ocular drug delivery. J. Pharm. Pharmacol. 47:703- 707, 1995.